Trends in the Distribution of Opioids in Puerto Rico, 1999-2013

Sausan El Burai Félix*, Karin A. Mack†, Christopher M. Jones‡

Objective: Limited information has been published about opioid prescribing practices in Puerto Rico. The objective of this study was to create baseline trends of opioids distributed over a period of fourteen years in Puerto Rico.

Methods: We examined data from the U.S. Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS) for the period 1999-2013. ARCOS data reflects the amount of controlled substances legally dispensed. Analyses include the distribution of opioids (in morphine milligram equivalent kg per 10,000 persons) by year and entity (pharmacy, hospital, practitioner).

Results: The distribution of four drugs (fentanyl, hydromorphone, methadone, oxycodone) increased over 100% between 1999 and 2013. The distribution of two drugs (hydrocodone and meperidine) declined between 1999 and 2013. Oxycodone distribution grew from 0.13 MME kg grams per 10,000 persons in 1999 to 0.29 MME kg in 2013.

Conclusion: ARCOS data showed that the overall amount of opioid pain relievers distributed in Puerto Rico increased by 68% between 1999 and 2013. Currently, prescription opioid pain reliever overdose deaths in Puerto Rico do not appear to be skyrocketing as they are in the mainland U.S. However, the ongoing problem with prescription opioid pain reliever overdoses in certain areas should serve as a warning to monitor consumption of opioid pain relievers, as well as changes in prescription drug abuse, overdoses, and deaths. [P R Health Sci J 2016;35:165-169]

Key words: Prescription drugs, Overdose

Opioids are medications that can be used to treat moderate-to-severe pain and are often prescribed following surgery, injury, or for pain related to health conditions such as cancer. Examples of these prescription medications include oxycodone (e.g., OxyContin, Percocet), hydrocodone (e.g., Vicodin), morphine, and codeine. In recent years, there has been an increase in the acceptance and use of prescription opioids for the treatment of chronic, non-cancer pain, such as back pain. Opioids are potentially addictive medications that have been associated with serious health outcomes. When abused, or combined with other drugs (especially those that depress respiration), outcomes can include overdose and death. Prescription opioids are reported to be abused in Puerto Rico, but to a lesser extent than cocaine, heroin, or marijuana (1, 2).

Based on survey data and treatment admissions, it appears that Puerto Rico has a lower rate of both prescription and illicit drug use and abuse than the U.S. mainland (3, 4). In 2010, there were 148 drug induced deaths in Puerto Rico (crude rate 4.0 per 100,000 persons), which is relatively low compared to the overall U.S. rate of 13.1 per 100,000 but comparable to the overall rate for Hispanic persons in the United States (5.5 per 100,000)(5).

While prescription opioid drug overdoses do not appear to be a public health crisis in Puerto Rico (2, 5), shifts in the availability of prescription drugs could signal an impending concomitant rise in adverse health outcomes including drug overdoses. The rapid increase in prescription drug-related overdose mortality in the mainland U.S. mirrored rising trends in distribution of those drugs (6). Limited information has been published about opioid pain reliever prescribing practices in Puerto Rico. The lack of availability of opioids for treating cancer pain in Latin America and the Caribbean (7,8) has been raised as a concern, however, data for Puerto Rico in particular was not available. Tracking the distribution of controlled substances can provide a baseline for public health action. The objective

*Center for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, Georgia, USA;
†Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Analysis, Research and Practice Integration, Atlanta, Georgia, USA;
‡Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, Silver Spring, Maryland

The authors have no conflicts of interest to disclose.

Address correspondence to: Karin A. Mack, 4770 Buford Hwy NE F62, Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Analysis, Research and Practice Integration, Atlanta, GA 30341. Email: kmack@cdc.gov
of this study was to create baseline trends of opioid pain relievers distributed between 1999-2013 in Puerto Rico. To our knowledge, no previous studies have provided this information.

**Methods**

The Automation of Reports and Consolidated Orders System (ARCOS) is an automated, comprehensive, mandatory reporting system that allows the U.S. Drug Enforcement Administration (DEA) to monitor certain controlled substances from the point of manufacture to the point of sale at the dispensing/retail level (9). Manufacturers must report inventories, acquisitions, and dispositions of all substances in Schedules I and II, and narcotic and Gamma-Hydroxybutyric Acid substances in Schedule III of the Controlled Substances Act. Data for this study for the years 1999-2013 were obtained by special request to the DEA and included distribution for these eight prescription opioid drugs: codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, and oxycodone. ARCOS tallies the cumulative sale of licit drugs in grams and reflects the amount legitimately distributed to pharmacies, hospitals, practitioners, and narcotic treatment centers. Drug acquisitions by narcotic treatment centers were excluded because these medications are used for substance abuse treatment.

Analyses include: overall distribution of eight drugs in kilograms (kg; converted from grams), as well as crude rates (morphine milligram equivalents (MME) distribution in kg per 10,000 persons). Puerto Rico population numbers used to calculate rates were obtained from the U.S. Census. Data by entity (pharmacy, hospital, practitioner) were not available for the year 2000, so analyses by entity uses 2001-2013 data. No personal identifying information was available in the database, and the study did not require human subjects review.

**Results**

Table 1 lists the total kgs distributed as well as crude rates for the eight drugs included in the analyses (codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine and oxycodone) by year. It also captures percent change between 1999 and 2013 in this distribution. The distribution of four drugs (fentanyl, hydromorphone, methadone, oxycodone) increased over 100% between 1999 and 2013. The distribution of two drugs (hydrocodone and meperidine) declined between 1999 and 2013. The distribution of codeine remained relatively level. Methadone had the largest percentage increase in distribution, although the 1999 rate was negligible (<.01 MME kg per 10,000 persons). Oxycodone distribution grew from 0.13 MME kg per 10,000 persons in 1999 to .29 MME kg in 2013.

Figure 1 displays rate (MME per 10,000 persons) of kg distribution by year for each of the eight drugs in a line graph. Oxycodone had the highest distribution in MME kg per 10,000 persons from 2001-2013. Both oxycodone and fentanyl distribution declined notably in 2008, but rebounded by 2010. We are not able to determine the nature of this drop with the data at hand. Hydromorphone and methadone distribution remained low throughout the time period.

Table 2 breaks down the distribution (rate in MME kg per 10,000 persons) of the eight drugs studied by entity (i.e., pharmacy, hospital, and practitioner). The bulk of drugs were distributed through pharmacies. Distribution to hospitals and practitioners was relatively stable between 1999 and 2013. Distribution to pharmacies was quite variable between 2006 and 2010, but there was a substantial increase between 2001 and 2013.

Table 1. Distribution of opioids in Puerto Rico, 1999-2013

<table>
<thead>
<tr>
<th>Year</th>
<th>Codeine</th>
<th>Fentanyl</th>
<th>Hydrocodone</th>
<th>Hydromorphone</th>
<th>Meperidine</th>
<th>Methadone</th>
<th>Morphine</th>
<th>Oxycodone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total kg</td>
<td>Rate</td>
<td>Total kg</td>
<td>Rate</td>
<td>Total kg</td>
<td>Rate</td>
<td>Total kg</td>
<td>Rate</td>
</tr>
<tr>
<td>1999</td>
<td>56.59</td>
<td>.02</td>
<td>4.04</td>
<td>.20</td>
<td>38.79</td>
<td>.10</td>
<td>43.53</td>
<td>.01</td>
</tr>
<tr>
<td>2000</td>
<td>na</td>
<td>na</td>
<td>.04</td>
<td>.24</td>
<td>35.82</td>
<td>.09</td>
<td>42.35</td>
<td>.01</td>
</tr>
<tr>
<td>2001</td>
<td>48.28</td>
<td>.02</td>
<td>.02</td>
<td>.22</td>
<td>30.55</td>
<td>.08</td>
<td>37.21</td>
<td>.01</td>
</tr>
<tr>
<td>2002</td>
<td>47.02</td>
<td>.02</td>
<td>.06</td>
<td>.30</td>
<td>25.09</td>
<td>.07</td>
<td>43.66</td>
<td>.01</td>
</tr>
<tr>
<td>2003</td>
<td>39.22</td>
<td>.02</td>
<td>.07</td>
<td>.36</td>
<td>21.87</td>
<td>.06</td>
<td>42.33</td>
<td>.01</td>
</tr>
<tr>
<td>2004</td>
<td>39.61</td>
<td>.02</td>
<td>.08</td>
<td>.40</td>
<td>21.76</td>
<td>.06</td>
<td>46.31</td>
<td>.01</td>
</tr>
<tr>
<td>2005</td>
<td>42.47</td>
<td>.02</td>
<td>.07</td>
<td>.38</td>
<td>18.96</td>
<td>.05</td>
<td>39.48</td>
<td>.01</td>
</tr>
<tr>
<td>2006</td>
<td>47.18</td>
<td>.02</td>
<td>.09</td>
<td>.47</td>
<td>19.68</td>
<td>.05</td>
<td>47.70</td>
<td>.01</td>
</tr>
<tr>
<td>2007</td>
<td>44.57</td>
<td>.02</td>
<td>.10</td>
<td>.52</td>
<td>17.36</td>
<td>.04</td>
<td>44.85</td>
<td>.01</td>
</tr>
<tr>
<td>2008</td>
<td>34.08</td>
<td>.01</td>
<td>.06</td>
<td>.34</td>
<td>12.29</td>
<td>.03</td>
<td>26.90</td>
<td>.01</td>
</tr>
<tr>
<td>2009</td>
<td>36.89</td>
<td>.01</td>
<td>.09</td>
<td>.47</td>
<td>11.70</td>
<td>.03</td>
<td>31.54</td>
<td>.01</td>
</tr>
<tr>
<td>2010</td>
<td>43.47</td>
<td>.02</td>
<td>.14</td>
<td>.69</td>
<td>12.55</td>
<td>.03</td>
<td>40.92</td>
<td>.01</td>
</tr>
<tr>
<td>2011</td>
<td>51.73</td>
<td>.02</td>
<td>.16</td>
<td>.76</td>
<td>13.12</td>
<td>.04</td>
<td>40.04</td>
<td>.01</td>
</tr>
<tr>
<td>2012</td>
<td>52.78</td>
<td>.02</td>
<td>.40</td>
<td>na</td>
<td>12.91</td>
<td>.04</td>
<td>37.52</td>
<td>.01</td>
</tr>
<tr>
<td>2013</td>
<td>57.28</td>
<td>.02</td>
<td>.17</td>
<td>.80</td>
<td>12.44</td>
<td>.03</td>
<td>38.11</td>
<td>.01</td>
</tr>
</tbody>
</table>

Percent Change

| 1999-2013 | 1.1% | 293.1% | -67.9% | 614.1% | -12.5% | 1125.7% | 7.4% | 100.6% |

El Burai Félix et al
**Figure 1.** Rate (morphine milligram equivalent kg per 10,000 persons) of distribution of opioids, Puerto Rico, Automation of Reports and Consolidated Orders System, 1999-2013

Note: codeine distribution not available in 2000; fentanyl, hydromorphone, and morphine not available in 2012.

**Figure 2.** Rate (morphine milligram equivalent kg per 10,000 persons) of distribution of opioids* to Pharmacies, Hospitals and Practitioner Offices, Puerto Rico, Automation of Reports and Consolidated Orders System, 2001-2013

*Opioids include those available in all years by entity: codeine, hydrocodone, meperidine, methadone, and oxycodone.
Discussion

Our analyses present trends in the distribution of prescription opioid pain relievers in Puerto Rico. ARCOS data showed that the overall amount of opioid pain relievers distributed in Puerto Rico increased by 68% between 1999 and 2013. Nonetheless, the overall distribution of these selected opioids in MME kg per person in 2013 is substantially lower than at the national level in the mainland U.S. (6).

The rise in opioid-related overdoses in the mainland U.S. relates closely to increased prescribing of these drugs during the past decade (10). The supply of pain medication must be such that there is enough for appropriate treatment for patients with pain. Treatment for cancer pain and end of life care is especially important, but the supply of prescription drugs may be limited by cost in lower income countries (11). López-Negrón and Monsanto-Planadeball found that prescription drug expenditures comprised nearly one-fifth of the personal expenditures of the elderly in Ponce, Puerto Rico (12). Thus, availability and monitoring must find the balance between appropriate care, affordability, and overdose/use.

Puerto Rico has several substance abuse prevention initiatives. The Puerto Rico Mental Health and Anti-Addiction Services Administration (Administración de Servicios de Salud Mental y Contra la Adicción) ensures the provision of mental health and substance use disorder prevention, treatment, and rehabilitation services. The agency administers services including ambulatory care, mental health centers, peer counseling, and methadone treatment. Puerto Rico uses Programa de Salones Especializados en Sustancias Controladas, or Drug Courts, which seek to rehabilitate individuals and reduce recidivism related to the abuse of controlled substances by providing addiction treatment services.

Puerto Rico has also begun the process to enact legislation to establish a Prescription Drug Monitoring Program (PDMP) to address prescription drug abuse and diversion. PDMPs are state-run electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients (13). They are designed to monitor prescribing for suspected abuse or diversion and can give a prescriber critical information regarding a patient’s prescription history. This information can help prescribers identify high-risk patients who would benefit from early interventions. The Programa de Monitoria de Recetas de Medicamentos Controlados is expected to be housed in the Department of Justice, and is projected to use an electronic system to collect data on controlled substances under schedules II, III, IV & V (14).

One limitation of the ARCOS data is an over-representation of drug consumption because unknown quantities are used for veterinary purposes, and the system includes amounts re-ordered to replace drugs stolen from pharmacies. ARCOS data had certain gaps; in particular we were not able to obtain a breakdown of distribution by entity for 1999 and 2000, and in addition, codeine distribution was not available in 2000 and fentanyl, hydromorphone, and morphine were not available in 2012. This study examined different parts of the distribution chain of the licit opioid supply and did not directly assess individual use of prescription opioid pain relievers. Despite these limitations, we know of no other published reports on the legal distribution of opioids in Puerto Rico.

Conclusion

The ongoing problem with prescription opioid pain reliever overdoses in other parts of the world should serve as a warning to public health practitioners to monitor consumption of opioid pain relievers, as well as changes in prescription drug abuse, overdose, and death. Continued surveillance of all prescriptions drugs is a prudent measures to track use, but also to identify emerging trends, such as the misuse/abuse of xylazine found in recent studies in Puerto Rico (15). Effective measures to address prescription drug overdoses will likely need to be multifaceted and involve a wide range of stakeholders engaged in surveillance, improvement of clinical practice, as well as policy changes. Capacity to understand drug use patterns and studies of risk factors can be enhanced by examining the prescription histories of people who die from prescription drug overdoses to determine the specific factors, such as abuse, that might have contributed to their death.

Resumen

Objetivo: En Puerto Rico muy poca información ha sido publicada acerca de las prácticas de prescripción de opioides. El objetivo de este estudio fue identificar tendencias básicas de opioides selectos, distribuidos durante un periodo de catorce años en Puerto Rico. Métodos: Examinamos los datos del «Automation of Reports and Consolidated Orders System» (ARCOS) de la Administración para el Control de Drogas de EE. UU. para el periodo 1999-2013. Los datos de ARCOS revelan la cantidad de sustancias controladas dispensadas legalmente. Nuestros análisis incluyen la distribución de opioides (miligramos equivalentes de morfina) por kg por cada 10,000 personas) por año y entidad (farmacia, hospital, y profesional médico). Resultados: La distribución de las cuatro drogas seleccionadas (fentanilo, hidromorfona, metadona, oxicodeona) aumentó más de 100% entre 1999 y 2013. La distribución de la hidrocodona y meperidina disminuyó durante el mismo periodo de tiempo. La distribución de oxicodeona aumentó de 0.13 kg MME por 10,000 personas en 1999 a 0.29 kg MME en 2013. Conclusión: Los datos de ARCOS mostraron que la cantidad global de opioids analgésicos (calmantes para el dolor) distribuida en Puerto Rico aumentó un 68% entre 1999 y 2013. Las muertes causadas por sobredosis de opioids analgésicos en la actualidad no parecen estar aumentado tan rápido en comparación con Estados Unidos. Sin embargo, el problema actual de sobredosis causadas por opioides analgésicos recetados en ciertas áreas,
debería servir como advertencia para controlar el consumo de éstos, así como cambios en el abuso de drogas recetadas, su abuso, y muertes.

Disclaimer: The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Food and Drug Administration.

References


